425. Lentiviral Vector Platforrm To Develop Anti-Cancer Immunotherapies
نویسندگان
چکیده
منابع مشابه
Lentiviral Vector
A retroviral vector system based on the human immunodeficiency virus (HIV) was developed that, in contrast to a murine leukemia virus-based counterpart, transduced heterologous sequences into HeLa cells and rat fibroblasts blocked in the cell cycle, as well as into human primary macrophages. Additionally, the HIV vector could mediate stable in vivo gene transfer into terminally differentiated n...
متن کاملLentiviral Vector Gene Transfer to Porcine Airways
In this study, we investigated lentiviral vector development and transduction efficiencies in well-differentiated primary cultures of pig airway epithelia (PAE) and wild-type pigs in vivo. We noted gene transfer efficiencies similar to that observed for human airway epithelia (HAE). Interestingly, feline immunodeficiency virus (FIV)-based vectors transduced immortalized pig cells as well as pig...
متن کاملHow to develop better screens for anti-cancer therapies?
The clinical efficacy of chemotherapy relies in part on its ability to potentiate anti-tumor immune responses. Recent work shows that several chemotherapeutic drugs induce intra-tumoral expression of lymphocyte-attracting chemokines, leading to clinical responses. Here, we argue that such knowledge should be used to screen for novel anti-tumor treatments.
متن کاملLentiviral vector-based therapy in head and neck cancer (Review)
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common neoplasm worldwide. Despite advances in multimodality treatments involving surgery, radiation and chemotherapy, the five-year survival rate has remained at ~50% for the past 35 years. Therefore, the early detection of recurrent or persistent disease is extremely important. Replication-incompetent HIV-1-based lentiviral vecto...
متن کاملEpigenetic Strategies to Boost Cancer Immunotherapies
Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunoth...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Therapy
سال: 2015
ISSN: 1525-0016
DOI: 10.1016/s1525-0016(16)34034-5